Trial Profile

A multicentre, Open Label, Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 26 Oct 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adalimumab (Primary)
Indications Crohn's disease
Focus Adverse reactions
Acronyms ACCESS
Sponsors Abbott Laboratories

Most Recent Events

27 Sep 2016 Results of pooled analysis from this and other nine trials (CLASSIC I and II, GAIN, CHARM, EXTEND, CARE, ACCESS, ADHERE) assessing the risk of serious and opportunistic infections in patients with treated with adalimumab (n=2266) published in the American Journal of Gastroenterology.
05 Nov 2009 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com